Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points.
Su J, Li M, He L, Zhao D, Wan W, Liu Y, Xu J, Xu J, Liu H, Jiang L, Wu H, Zuo X, Huang C, Liu X, Li F, Zhang Z, Liu X, Dong L, Li T, Chen H, Li J, He D, Lu X, Huang A, Tao Y, Wang Y, Zhang Z, Wei W, Li X, Zeng X.
Su J, et al. Among authors: wang y.
Front Pharmacol. 2020 Dec 7;11:606497. doi: 10.3389/fphar.2020.606497. eCollection 2020.
Front Pharmacol. 2020.
PMID: 33364967
Free PMC article.